Sur cette page
CRSP CRISPR Therapeutics AG - Common Shares
NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 3, 2026
$55,43
· % de la fourchette 52 sem.
· au-dessus du plus bas
· vers le haut
$44,12Bas 52 semaines
$78,48Haut 52 semaines
Capitalisation Boursière (MRQ)
$5.36B
P/E (TTM)
-11.8
BPA (TTM)
$-4.71
Revenu (TTM)
$13M
vos badges
Fourchette 52 semaines
$44–$78
Note des analystes
BUY
Objectif de cours
$88
P/E
-11.8
ROE
-26.1%
Marge nette
-3368.7%
Votre barre de badges est vide — épinglez une métrique n'importe où sur cette page.
CRSP Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$55.43
Capitalisation Boursière (MRQ)
$5.36B
P/E (TTM)
-11.8
BPA (TTM)
$-4.71
Revenu (TTM)
$13M
ROE (TTM)
-26.1%
Fourchette 52 semaines
$44–$78
CRSP Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
fourchette
barres
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
À propos de CRISPR Therapeutics AG - Common Shares Présentation de l'entreprise depuis Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
secteurHealthcare
industrieBiotechnology
paysCH
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenu$4M2016-12-31 → 2025-12-31
BPA$-6.472017-12-31 → 2025-12-31
Flux de trésorerie libre$-346M2016-12-31 → 2025-12-31
Marge nette-3368.7%2016-12-31 → 2025-12-31
Valorisation et Ratios
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | CRSP | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -11.8moyenne 5 ans ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 400.1moyenne 5 ans ≈841.4 | ≈841.4 | · | · | |
| P/B (MRQ) | 3.1moyenne 5 ans ≈2.2 | ≈2.2 | · | · | |
| Cours / FCF (TTM) | -14.4moyenne 5 ans ≈-9.9 | ≈-9.9 | · | · | |
| Cours / Flux de trésorerie (TTM) | -14.5moyenne 5 ans ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book (Cours / Actif net tangible) | 2.8moyenne 5 ans ≈2.2 | ≈2.2 | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | CRSP | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | -3990.0%moyenne 5 ans ≈-15278.7% | ≈-15278.7% | · | · | |
| Marge EBITDA (TTM) | -3850.4%moyenne 5 ans ≈-14752.4% | ≈-14752.4% | · | · | |
| Marge avant impôts (TTM) | -3346.1%moyenne 5 ans ≈-14347.2% | ≈-14347.2% | · | · | |
| Marge nette (TTM) | -3368.7%moyenne 5 ans ≈-14364.6% | ≈-14364.6% | · | · | |
| ROA (TTM) | -19.3%moyenne 5 ans ≈-11.7% | ≈-11.7% | -40.4% | Premier rang | |
| ROE (TTM) | -26.1%moyenne 5 ans ≈-15.6% | ≈-15.6% | -46.3% | Premier rang | |
| ROIC | -34.8%moyenne 5 ans ≈-18.3% | ≈-18.3% | -57.7% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | CRSP | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Ratio de liquidité (MRQ) | 17.8moyenne 5 ans ≈17.7 | ≈17.7 | 7.8 | Liquidité solide | |
| Quick Ratio (Ratio de liquidité réduite) | 13.2moyenne 5 ans ≈17.5 | ≈17.5 | 6.5 | Liquidité solide |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | CRSP | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | -90.6%moyenne 5 ans ≈31552.0% | ≈31552.0% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 43.1%moyenne 5 ans ≈226.6% | ≈226.6% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 37.3% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | CRSP | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.0moyenne 5 ans ≈0.1 | ≈0.1 | · | · | |
| Receivables Turnover (Rotation des créances) | 0.3moyenne 5 ans ≈817.5 | ≈817.5 | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.09%
Prochain rapport
Nov 09, 2026
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 10, 2026 | $-0.94 | $-1.22 | 23.0% |
| 31 mars 2026 | $-1.28 | $-1.25 | -2.5% | |
| 31 décembre 2025 | $-1.37 | $-1.18 | -16.4% | |
| 30 septembre 2025 | $-1.17 | $-1.29 | 9.0% | |
| 30 juin 2025 | $-1.29 | $-1.45 | 11.2% | |
| 31 mars 2025 | $-1.58 | $-1.28 | -23.9% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.04 | $22.53 | $23.52 | $23.89 | $31.17 | $22.52 | $15.46 | $7.56 | $4.63 | $5.86 | · | |
| Revenue / Share | $0.04 | $0.44 | $4.69 | $0.02 | $11.38 | $0.01 | $5.09 | · | · | · | · | |
| Cash Flow / Share | $-3.84 | $-1.69 | $-3.29 | $-6.38 | $6.70 | $-3.61 | $1.00 | · | · | · | · | |
| Cash / Share | $3.62 | $3.48 | $4.87 | $2.70 | $11.99 | $15.81 | $15.53 | $8.81 | $5.91 | $7.94 | · | |
| EPS (TTM) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-7.05 | · |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.07 | $18.83 | · | $20.41 | $19.36 | $21.18 | · | $22.73 | $23.29 | $24.56 | · | $21.75 | $22.88 | $23.52 | · | $24.97 | |
| Revenue / Share | $0.11 | $0.02 | · | $0.01 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.00 | $0.89 | $1.27 | · | $0.00 | |
| Cash Flow / Share | · | $-1.13 | · | · | · | $-0.63 | · | · | · | $1.34 | · | · | · | $0.11 | · | · | |
| Cash / Share | $3.01 | $4.39 | · | $3.05 | $2.19 | $2.72 | · | $2.64 | $5.70 | $8.34 | · | $6.64 | $5.60 | $4.37 | · | $6.32 | |
| EPS (TTM) | $-4.71 | $-6.17 | · | $-5.56 | $-5.40 | $-4.49 | · | $-2.81 | $-3.21 | $-2.70 | · | $-4.46 | $-5.29 | $-6.71 | · | $-8.52 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $38M | $38M | $38M | · | $203M | $202M | $272M | · | $170M | $170M | $100M | · | $14M | |
| Net Income TTM | $-451M | $-569M | · | $-488M | $-468M | $-386M | · | $-240M | $-266M | $-217M | · | $-354M | $-416M | $-524M | · | $-681M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -11.6 | -7.7 | · | -11.7 | -9.0 | -7.6 | · | -16.7 | -16.8 | -25.2 | · | -10.2 | -10.6 | -6.7 | · | -7.7 | |
| P/S | 393.7 | 1117.5 | · | 158.7 | 113.0 | 78.0 | · | 19.8 | 22.7 | 21.3 | · | 21.2 | 26.2 | 35.6 | · | 362.9 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| Earnings Yield | -8.6% | -13.0% | · | -8.6% | -11.1% | -13.2% | · | -6.0% | -5.9% | -4.0% | · | -9.8% | -9.4% | -14.8% | · | -13.0% |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $4M | $37M | $371M | $1M | $915M |
| Marge d'exploitation % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Résultat net | $-582M | $-366M | $-154M | $-650M | $378M |
| BPA dilué | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio de liquidité | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Ratio de liquidité réduite | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-346M | $-145M | $-270M | $-533M | $457M |
Détenteurs institutionnels (13F) 572 déclarants · $4.3B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Détenteurs
572
Valeur détenue
$4.3B
Nouvelles positions
82
Positions clôturées
47
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 82 (-14 vs T. préc.) | 47 (-13 vs T. préc.) | 158 (-19 vs T. préc.) | 157 (+29 vs T. préc.) | -2.0M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| ARK Investment Management LLC | $515 999 631 | 9 460 939 | 12,01% | Actions |
| BlackRock, Inc. | $455 353 197 | 8 348 977 | 10,60% | Actions |
| Orbis Allan Gray Ltd | $297 197 241 | 5 449 161 | 6,92% | Actions |
| Capital World Investors | $259 039 094 | 4 749 525 | 6,03% | Actions |
| STATE STREET CORP | $235 703 664 | 4 321 666 | 5,49% | Actions |
| GSK plc | $175 652 997 | 3 220 627 | 4,09% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $136 919 043 | 2 509 915 | 3,19% | Actions |
| VANGUARD GROUP INC | $118 954 581 | 2 268 394 | 2,77% | Actions |
| SR One Capital Management, LP | $111 194 134 | 2 038 763 | 2,59% | Actions |
| TWO SIGMA INVESTMENTS, LP | $108 459 389 | 1 988 621 | 2,53% | Actions |
| FMR LLC | $104 089 735 | 1 908 503 | 2,42% | Actions |
| Sumitomo Mitsui Trust Group, Inc. | $93 848 832 | 1 720 734 | 2,19% | Actions |
| Amova Asset Management Americas, Inc. | $93 762 487 | 1 720 097 | 2,18% | Actions |
| EcoR1 Capital, LLC | $75 771 113 | 1 389 276 | 1,76% | Actions |
| UBS Group AG | $71 856 395 | 1 317 499 | 1,67% | Actions |
| Capital International Investors | $69 178 918 | 1 268 407 | 1,61% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $64 457 935 | 1 181 847 | 1,50% | Actions |
| BANK OF AMERICA CORP /DE/ | $62 999 405 | 1 155 105 | 1,47% | Actions |
| NEA Management Company, LLC | $57 734 408 | 1 058 570 | 1,34% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57 694 430 | 1 057 837 | 1,34% | Actions |
| D. E. Shaw & Co., Inc. | $48 748 506 | 893 812 | 1,13% | Actions |
| MORGAN STANLEY | $47 992 455 | 879 949 | 1,12% | Actions |
| NORTHERN TRUST CORP | $47 072 983 | 863 091 | 1,10% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35 380 807 | 648 713 | 0,82% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $31 089 982 | 570 040 | 0,72% | Actions |
| CITADEL ADVISORS LLC | $25 404 514 | 465 796 | 0,59% | Actions |
| JPMORGAN CHASE & CO | $24 569 275 | 431 669 | 0,57% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 298 288 | 427 178 | 0,54% | Actions |
| MILLENNIUM MANAGEMENT LLC | $20 836 025 | 382 032 | 0,49% | Actions |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20 833 789 | 381 991 | 0,49% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18 456 336 | 338 400 | 0,43% | Option de vente |
| Bank of New York Mellon Corp | $17 821 531 | 326 761 | 0,41% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17 763 678 | 325 700 | 0,41% | Option d'achat |
| Logos Global Management LP | $16 362 000 | 300 000 | 0,38% | Actions |
| CITADEL ADVISORS LLC | $15 822 054 | 290 100 | 0,37% | Option de vente |
| Squarepoint Ops LLC | $15 641 472 | 286 789 | 0,36% | Actions |
| Jump Financial, LLC | $15 159 502 | 277 952 | 0,35% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $15 034 803 | 275 375 | 0,35% | Actions |
| GOLDMAN SACHS GROUP INC | $14 855 182 | 272 372 | 0,35% | Actions |
| NORGES BANK | $14 767 032 | 270 756 | 0,34% | Actions |
| WELLS FARGO & COMPANY/MN | $14 353 246 | 263 169 | 0,33% | Actions |
| CITADEL ADVISORS LLC | $13 973 148 | 256 200 | 0,33% | Option d'achat |
| AMERIPRISE FINANCIAL INC | $13 669 977 | 250 614 | 0,32% | Actions |
| Vestmark Advisory Solutions, Inc. | $13 213 188 | 242 266 | 0,31% | Actions |
| RAYMOND JAMES FINANCIAL INC | $12 652 626 | 231 988 | 0,29% | Actions |
| JANE STREET GROUP, LLC | $12 566 016 | 230 400 | 0,29% | Option d'achat |
| PEAK6 LLC | $11 633 382 | 213 300 | 0,27% | Option de vente |
| Nuveen, LLC | $11 076 474 | 203 089 | 0,26% | Actions |
| ROYAL BANK OF CANADA | $9 438 000 | 173 045 | 0,22% | Actions |
| Marex Group Ltd | $9 303 652 | 170 584 | 0,22% | Actions |
Activistes et détenteurs de 5%+ 6 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 dépôts | 16 février 2021 | · | Dépôt initial | · | SEC |
| GlaxoSmithKline plc ×5 dépôts | 10 juillet 2020 | · | Dépôt initial | · | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 dépôts | 4 février 2020 | · | Dépôt initial | · | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 dépôts | 7 juin 2019 | · | Dépôt initial | · | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 dépôts | 8 février 2018 | · | Dépôt initial | · | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 dépôts | 16 janvier 2018 | · | Dépôt initial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 32 initiés · 12 dirigeants · 16 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 mars 2026 M | 255 501 | 0 | 9 | $-10 756 932 |
| Brendan Smith | Chief Financial Officer | 18 février 2023 M | 5 072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 mars 2021 M | 1 891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 mars 2025 M | 10 544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 août 2022 A | 26 797 | 0 | 0 | $0 |
| James R. Kasinger | General Counsel and Secretary | 22 septembre 2026 M | 94 784 | 0 | 6 | $-1 272 398 |
| Naimish Patel | Chief Medical Officer | 29 mai 2026 A | 19 357 | 1 | 2 | $-312 892 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 octobre 2023 A | 4 411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 décembre 2021 M | 52 364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 janvier 2018 M | 25 204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 juin 2017 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 octobre 2016 C | 505 617 | 0 | 0 | $0 |
| Ali Behbahani | Administrateur | 17 septembre 2026 M | 16 637 | 0 | 1 | $-780 934 |
| Christian Rommel | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| Harold Edward Fleming | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| Douglas A Treco | Administrateur | 5 juin 2026 A | 22 000 | 0 | 0 | $0 |
| Briggs Morrison | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| Katherine A High | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| John Greene | Administrateur | 5 juin 2026 A | 7 000 | 0 | 0 | $0 |
| Simeon George | Administrateur | 5 juin 2026 A | 1 730 179 | 0 | 0 | $0 |
| Maria Fardis | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| Sandesh Mahatme | Administrateur | 5 juin 2026 A | · | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Administrateur | 9 juin 2022 A | 148 831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Administrateur | 19 novembre 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Administrateur | 18 décembre 2018 S | 1 171 268 | 0 | 0 | $0 |
| Thomas Woiwode | Administrateur | 15 juin 2018 A | 640 014 | 0 | 0 | $0 |
| Anthony N Coles | Administrateur | 31 mai 2017 A | 70 000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Détenteur de 10% | 4 décembre 2017 S | 3 722 534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Détenteur de 10% | 24 octobre 2016 C | 744 380 | 0 | 0 | $0 |
| GSK plc | Détenteur de 10% | 24 octobre 2016 C | 3 220 627 | 0 | 0 | $0 |
| Raju Prasad | · | 7 août 2026 G | 14 815 | 0 | 10 | $-5 100 841 |
| Rodger Novak | · | 30 juin 2021 S | 573 007 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 27 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,53% | 22 018 NS | 31 juillet 2026 | N-PORT |
| IDNA · iShares Trust | 1,46% | 71 206 SH | 11 septembre 2026 | Quotidien |
| LABU · Direxion Shares ETF Trust | 0,66% | 68 253 NS | 31 juillet 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 6 830 SH | 2 octobre 2026 | Quotidien |
| IBB · iShares Trust | 0,35% | 685 566 SH | 11 septembre 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70 696 SH | 19 août 2026 | Quotidien |
| IWM · iShares Trust | 0,16% | 2 381 008 SH | 11 septembre 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536 446 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,14% | 44 639 NS | 31 juillet 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,11% | 6 887 SH | 2 octobre 2026 | Quotidien |
| ESML · iShares Trust | 0,06% | 34 534 SH | 11 septembre 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1 106 455 SH | 19 août 2026 | Quotidien |
| WSML · iShares Trust | 0,04% | 5 543 SH | 11 septembre 2026 | Quotidien |
| IWO · iShares Trust | 0,04% | 115 267 SH | 11 septembre 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13 170 SH | 19 août 2026 | Quotidien |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 1 727 SH | 2 octobre 2026 | Quotidien |
| XT · iShares Trust | 0,03% | 21 859 SH | 11 septembre 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 774 SH | 19 août 2026 | Quotidien |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20 627 SH | 19 août 2026 | Quotidien |
| IYY · iShares Trust | 0,01% | 4 231 SH | 11 septembre 2026 | Quotidien |
| ITOT · iShares Trust | 0,01% | 128 500 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,01% | 25 737 SH | 11 septembre 2026 | Quotidien |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75 392 SH | 19 août 2026 | Quotidien |
| IWN · iShares Trust | · | 760 375 SH | 11 septembre 2026 | Quotidien |
| ISCB · iShares Trust | · | 4 191 SH | 11 septembre 2026 | Quotidien |
| ISCV · iShares Trust | · | 20 690 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 58 519 SH | 11 septembre 2026 | Quotidien |
CRSP Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
notation · 28 analystes
ACHAT
Objectif médian
$80.00
+44,3%
6 21,4%
Achat fort
11 39,3%
Achat
11 39,3%
Conserver
0 0,0%
Vente
0 0,0%
Vente forte
Objectif de cours à 12 mois
18 analystes · 2026-10-03Objectif moyen $87.56 +58,0%
Maintenant
Prix actuel $55.43
Bas$44.00
Moyenne$87.56
Haut$291.00
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
Dernières actualités Actualités récentes mentionnant cette entreprise
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Nasdaq · 3 semaines, 1 jour il y a
Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
Yahoo Finance · 2 mois, 2 semaines il y a
2 Beaten-Down Stocks With Massive Upside Potential
Nasdaq · 2 mois, 3 semaines il y a
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Yahoo Finance · 3 mois, 3 semaines il y a
L'action CRISPR Therapeutics est ridiculement bon marché -- Voici pourquoi les analystes prévoient un potentiel de hausse de 437 %
Nasdaq · 4 mois il y a
Leadership de la croissance Mega‑Cap ou potentiel de la petite capitalisation ? VUG vs. VBK
Nasdaq · 4 mois il y a
1 Un analyste de Wall Street pense que CRISPR Therapeutics pourrait plus que doubler. Devriez-vous acheter l'action à tout prix ?
Yahoo Finance · 4 mois, 2 semaines il y a
Sortie notable d'ETF détectée - ARKK, CRSP, TEM, HOOD
Nasdaq · 5 mois, 2 semaines il y a
Cette biotechnologie a un pipeline qui pourrait redéfinir toute sa zone thérapeutique
Nasdaq · 5 mois, 3 semaines il y a
Cathie Wood Chasse les Bonnes Affaires : 2 Actions Qu'elle Vient d'Acheter
Nasdaq · 5 mois, 3 semaines il y a
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Source : Dépôt SEC 10-Q le Aoû 3, 2026